Logo image of 1COV.DE

COVESTRO AG (1COV.DE) Stock Fundamental Analysis

Europe - FRA:1COV - DE0006062144 - Common Stock

59.26 EUR
-0.28 (-0.47%)
Last: 10/27/2025, 5:29:57 PM
Fundamental Rating

2

Overall 1COV gets a fundamental rating of 2 out of 10. We evaluated 1COV against 68 industry peers in the Chemicals industry. 1COV has a bad profitability rating. Also its financial health evaluation is rather negative. 1COV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

1COV had negative earnings in the past year.
1COV had a positive operating cash flow in the past year.
In multiple years 1COV reported negative net income over the last 5 years.
In the past 5 years 1COV always reported a positive cash flow from operatings.
1COV.DE Yearly Net Income VS EBIT VS OCF VS FCF1COV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

1.2 Ratios

1COV has a Return On Assets of -2.86%. This is in the lower half of the industry: 1COV underperforms 70.59% of its industry peers.
With a Return On Equity value of -6.14%, 1COV is not doing good in the industry: 72.06% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -2.86%
ROE -6.14%
ROIC N/A
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
1COV.DE Yearly ROA, ROE, ROIC1COV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

1COV's Operating Margin has declined in the last couple of years.
1COV has a Gross Margin of 14.09%. This is in the lower half of the industry: 1COV underperforms 76.47% of its industry peers.
1COV's Gross Margin has declined in the last couple of years.
1COV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.09%
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
1COV.DE Yearly Profit, Operating, Gross Margins1COV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

3

2. Health

2.1 Basic Checks

1COV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 1COV has about the same amount of shares outstanding.
1COV has more shares outstanding than it did 5 years ago.
1COV has a better debt/assets ratio than last year.
1COV.DE Yearly Shares Outstanding1COV.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
1COV.DE Yearly Total Debt VS Total Assets1COV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

1COV has an Altman-Z score of 2.34. This is not the best score and indicates that 1COV is in the grey zone with still only limited risk for bankruptcy at the moment.
1COV has a Altman-Z score of 2.34. This is comparable to the rest of the industry: 1COV outperforms 52.94% of its industry peers.
A Debt/Equity ratio of 0.34 indicates that 1COV is not too dependend on debt financing.
1COV's Debt to Equity ratio of 0.34 is fine compared to the rest of the industry. 1COV outperforms 61.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z 2.34
ROIC/WACCN/A
WACC6.39%
1COV.DE Yearly LT Debt VS Equity VS FCF1COV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

1COV has a Current Ratio of 1.39. This is a normal value and indicates that 1COV is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.39, 1COV is not doing good in the industry: 66.18% of the companies in the same industry are doing better.
1COV has a Quick Ratio of 1.39. This is a bad value and indicates that 1COV is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of 1COV (0.74) is worse than 77.94% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 0.74
1COV.DE Yearly Current Assets VS Current Liabilites1COV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

3

3. Growth

3.1 Past

1COV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.54%.
Looking at the last year, 1COV shows a decrease in Revenue. The Revenue has decreased by -1.98% in the last year.
Measured over the past years, 1COV shows a small growth in Revenue. The Revenue has been growing by 2.70% on average per year.
EPS 1Y (TTM)-17.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.42%
Revenue 1Y (TTM)-1.98%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-8.43%

3.2 Future

Based on estimates for the next years, 1COV will show a very strong growth in Earnings Per Share. The EPS will grow by 20.27% on average per year.
Based on estimates for the next years, 1COV will show a small growth in Revenue. The Revenue will grow by 0.72% on average per year.
EPS Next Y-7.01%
EPS Next 2Y60.31%
EPS Next 3Y48.4%
EPS Next 5Y20.27%
Revenue Next Year-6.95%
Revenue Next 2Y-1.93%
Revenue Next 3Y-0.15%
Revenue Next 5Y0.72%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
1COV.DE Yearly Revenue VS Estimates1COV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B
1COV.DE Yearly EPS VS Estimates1COV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6 8

1

4. Valuation

4.1 Price/Earnings Ratio

1COV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 73.23, which means the current valuation is very expensive for 1COV.
67.65% of the companies in the same industry are cheaper than 1COV, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of 1COV to the average of the S&P500 Index (22.99), we can say 1COV is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 73.23
1COV.DE Price Earnings VS Forward Price Earnings1COV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, 1COV is valued a bit more expensive than the industry average as 63.24% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.12
1COV.DE Per share data1COV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

1COV's earnings are expected to grow with 48.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.31%
EPS Next 3Y48.4%

0

5. Dividend

5.1 Amount

No dividends for 1COV!.
Industry RankSector Rank
Dividend Yield N/A

COVESTRO AG

FRA:1COV (10/27/2025, 5:29:57 PM)

59.26

-0.28 (-0.47%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)10-30 2025-10-30
Inst Owners25.07%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap11.20B
Revenue(TTM)13.84B
Net Income(TTM)-378000000
Analysts49.47
Price Target61.98 (4.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.01
Dividend Growth(5Y)-70.61%
DP-0.26%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-681.03%
Min EPS beat(2)-1222.75%
Max EPS beat(2)-139.31%
EPS beat(4)1
Avg EPS beat(4)-330.2%
Min EPS beat(4)-1222.75%
Max EPS beat(4)201.01%
EPS beat(8)1
Avg EPS beat(8)-4314.94%
EPS beat(12)2
Avg EPS beat(12)-2882.46%
EPS beat(16)4
Avg EPS beat(16)-2161.83%
Revenue beat(2)0
Avg Revenue beat(2)-5.71%
Min Revenue beat(2)-6.91%
Max Revenue beat(2)-4.5%
Revenue beat(4)0
Avg Revenue beat(4)-5.8%
Min Revenue beat(4)-6.91%
Max Revenue beat(4)-4.5%
Revenue beat(8)0
Avg Revenue beat(8)-4.99%
Revenue beat(12)1
Avg Revenue beat(12)-3.71%
Revenue beat(16)4
Avg Revenue beat(16)-2.08%
PT rev (1m)-0.16%
PT rev (3m)-1.51%
EPS NQ rev (1m)-18.93%
EPS NQ rev (3m)-218.18%
EPS NY rev (1m)0%
EPS NY rev (3m)-577.27%
Revenue NQ rev (1m)-4.92%
Revenue NQ rev (3m)-9.65%
Revenue NY rev (1m)-2.77%
Revenue NY rev (3m)-8.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 73.23
P/S 0.81
P/FCF N/A
P/OCF 14.78
P/B 1.82
P/tB 2.23
EV/EBITDA 16.12
EPS(TTM)-2.01
EYN/A
EPS(NY)0.81
Fwd EY1.37%
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)4.01
OCFY6.77%
SpS73.2
BVpS32.56
TBVpS26.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.86%
ROE -6.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.09%
FCFM N/A
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)6.03%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
F-Score4
Asset Turnover1.05
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA 2.39
Cap/Depr 88.46%
Cap/Sales 6.32%
Interest Coverage N/A
Cash Conversion 85.65%
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 0.74
Altman-Z 2.34
F-Score4
WACC6.39%
ROIC/WACCN/A
Cap/Depr(3y)75.52%
Cap/Depr(5y)82.02%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.42%
EPS Next Y-7.01%
EPS Next 2Y60.31%
EPS Next 3Y48.4%
EPS Next 5Y20.27%
Revenue 1Y (TTM)-1.98%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-8.43%
Revenue Next Year-6.95%
Revenue Next 2Y-1.93%
Revenue Next 3Y-0.15%
Revenue Next 5Y0.72%
EBIT growth 1Y-183.74%
EBIT growth 3Y-79.32%
EBIT growth 5Y-52.83%
EBIT Next Year267.68%
EBIT Next 3Y84.36%
EBIT Next 5Y41.79%
FCF growth 1Y-126.73%
FCF growth 3Y-60.36%
FCF growth 5Y-28.37%
OCF growth 1Y-37.61%
OCF growth 3Y-26.52%
OCF growth 5Y-8.84%

COVESTRO AG / 1COV.DE FAQ

What is the fundamental rating for 1COV stock?

ChartMill assigns a fundamental rating of 2 / 10 to 1COV.DE.


What is the valuation status of COVESTRO AG (1COV.DE) stock?

ChartMill assigns a valuation rating of 1 / 10 to COVESTRO AG (1COV.DE). This can be considered as Overvalued.


Can you provide the profitability details for COVESTRO AG?

COVESTRO AG (1COV.DE) has a profitability rating of 1 / 10.


How financially healthy is COVESTRO AG?

The financial health rating of COVESTRO AG (1COV.DE) is 3 / 10.